Loading...

NVAX NOVAVAX INC Product Launches 8-K Filing

NVVX

NVX

NOVAVAX INC

(NVAX)

2025 8-K

Show Summary

Show Summary

Investor Meetings

New Product Launches

Financial Statements

Clinical Trials

FDA Application Update

Contract Termination

Investor Update

Quarterly Results

Investor Update

Contract Amendment

Investor Update

Financial Results

Settlement Agreement

FDA Clinical Hold

Market Clarification

Financial Results

Annual Meeting Results

Update for Investors and FD...

Management Changes

Collaboration and License A...

Financial Results

Settlement Agreement with F...

Financial Results

Termination and Settlement ...

Workforce Reduction

Results of Operations and F...

Lawsuit Alleging False Stat...

Appointments, Retirement

Financial Results

Disclosure of Say on Pay Votes

COVID-19 Vaccine Authorization

Financial Results

Settlement Agreement and Se...

Financial Results and Workf...

Amended and Restated By-Laws

Management Change

Banking Relationships

Management Change

Financial Results Announcement

External Links:

On May 16, 2025, Novavax announced FDA approval for its COVID-19 vaccine, triggering a $175 million payment from Sanofi, and plans for a new trial for ages 50-64. The company expects R&D and SG&A expenses between $475-$525 million for 2025, reducing to $350 million in 2026 and $250 million in 2027.

AI Assistant

NOVAVAX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.